Scientists from the University of Sheffield have developed a novel antibody-based therapy which targets the progression of life threating kidney fibrosis.
The ground breaking therapy works by blocking the action of a key enzyme and the treatment should also work for lung, liver and heart fibrosis.
The pioneering biological discovery was made by a research team led by Professor Tim Johnson and Dr Phil Watson, from the University's Academic Nephrology Unit in the Department of Infection and Immunity.
The research, conducted in collaboration with MRC Technology, targets a key step in the progression of fibrosis, which has led to the development of a fibrosis therapy programme and exclusive licensing agreement by global biopharmaceutical company UCB.
There is currently no cure for fibrosis, a primary cause of major organ failure, and a complicating factor in chronic diseases such as diabetes and hypertension.
Professor Johnson said: "The development of these therapeutic antibodies is the culmination of 20 years work to identify the role of a key target in the tissue scarring process where it is possible to understand its mechanism of action and then develop a way to specifically target it.
"This is a fantastic example of how MRC Technology can assist in translating laboratory research to the patient. I am delighted that UCB have licensed the humanised antibodies as the company's expertise in antibody development will ensure patients benefit from this new treatment in the shortest time possible."
He added: " It is also extremely important to recognise that this work would not have been possible without support from charities such as Kidney Research UK, Diabetes UK and the Wellcome trust who have all supported this work."
UCB New Medicines Vice President and Head of Immunology, Dr Mark Bodmer, said: "The program focuses on a key area of unmet medical need and we are committed to bringing fibrosis treatment to patients.
"We are excited to be working with MRC Technology and University of Sheffield scientists to build on their work to date in generating and characterising promising therapeutic approaches with the potential for significant patient impact."
Michael Dalrymple, Director of Business Development at MRC Technology, said: "We are delighted to be able to partner this program with UCB and we look forward to working together to ensure the project's commercial success. This program has the potential to not only benefit fibrosis patients and help prevent organ failure, but also enables MRC Technology and its partners to help bring other new research to market."
Revenue made from the licensing agreement will be shared back with the University and will be reinvested to support other collaborative programs within its drug discovery labs.
Notes for editors
University of Sheffield
With almost 25,000 of the brightest students from around 120 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world's leading universities.
A member of the UK's prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.
Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.
In 2011 it was named University of the Year in the Times Higher Education Awards and in the last decade has won four Queen's Anniversary Prizes in recognition of the outstanding contribution to the United Kingdom's intellectual, economic, cultural and social life.
Sheffield has five Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline and Siemens, as well as many UK and overseas government agencies and charitable foundations.
For further information, please visit http://www.sheffield.ac.uk
UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels.
MRC Technology is an independent life science technology transfer charity, offering professional services to organisations within the academic, charity, biotechnology and pharmaceutical sectors globally. Services include IP management and research and development for diagnostics, small molecules and therapeutic antibodies. MRC Technology bridges the gap between basic medical research and commercialisation, helping early discoveries progress to clinical application.
For further information please contact: Amy Pullan, Media Relations Officer, University of Sheffield, on 0114 222 9859 or alternatively email firstname.lastname@example.org
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.